Blood levels of o,p′-DDD following administration in various vehicles after a single dose and during long-term treatment
- 70 Downloads
Plasma levels of o,p′-DDD were measured after ingestion of a single oral dose. At the onset of therapy o,p′-DDD was administered as commercially available tablets and granules and in milk, chocolate, and an oil emulsion to 9, 12, 14, 10, and 6 patients, respectively. Following administration in chocolate, emulsion, and milk significantly higher mean plasma levels were recorded in the first 5-and 10-h periods than after tablets. Granules gave significantly lower plasma levels than all other forms.
Plasma levels were also measured during maintenance therapy, when a total of 200 g o,p′-DDD was administered to 22 patients with adrenocortical carcinoma. The plasma disappearance rate after termination of long-term therapy was found to be between 18 and 159 days.
The recovery of o,p′-DDD from faeces was about five times higher after ingestion of tablets than after administration in oil emulsion and milk.
As far as the rapid increase in plasma levels and patient compliance are concerned, the best results were obtained with the milk powder mixture.
KeywordsCarcinoma Cancer Research Plasma Level Single Dose Oral Dose
Unable to display preview. Download preview PDF.
- 1.Armitage PH (1980) Statistical methods in medical research. Blackwell, OxfordGoogle Scholar
- 2.Bar-Hay J, Benderly A, Rumney G (1964) Treatment of a case of nontumourous Cushing's syndrome with o,p′-DDD. Pediatrics 33: 239–244Google Scholar
- 3.Bergenstal DM, Lipsett MB, Moy RH, Hertz R (1959) Regression of adrenal cortical cancer and suppression of adrenal cortical functions in man by o,p′-DDD. Trans Assoc Am Physicians 72: 341–350Google Scholar
- 4.Hogan TF, Citrin DL, Johnson BM, Nakamura S, Davies TE, Borden EC (1978) o,p′-DDD therapy of adrenal cortical carcinoma. Cancer 42: 2177–2181Google Scholar
- 5.Hutter AM, Kayhoe DE (1966) Adrenal cortical carcinoma. Am J Med 41: 572–580Google Scholar
- 6.Lubitz JA, Freeman L, Okun R (1975) Mitotane use in inoperable adrenal cortical cancer. JAMA 233: 1109–1112Google Scholar
- 7.Luton JP, Mahoudeau JA, Bouchard P (1979) Treatment of Cushing's disease by o,p′-DDD. N Engl J Med 300: 459–464Google Scholar
- 8.Moolenaar AJ, van Seters AP (1975) o,p′-DDD values in plasma and tissue during and after chemotherapy of adrenocortical carcinoma. Acta Endocrinol [Suppl] (Copenh) 199: 226–232Google Scholar
- 9.Moolenaar AJ, Niewint JWM, Oei IT (1977) Estimations of o,p′-DDD in plasma by gas liquid chromatography. Clin Chim Acta 76: 213–218Google Scholar
- 10.Moy RH (1961) Studies of pharmacology of o,p′-DDD in man. J Lab Clin Med 58: 296–304Google Scholar
- 11.Nissen-Meyer R, Vogt JH (1972) In: Binder C, Hall PE (eds) Cushing's syndrome. Diagnosis and treatment. Heinemann, Chemotherapy. London, pp 141–147Google Scholar
- 12.Oettinger WF, Sharpless NF (1946) The toxicity and toxic manifestations of 2,2-bis(p-chlorophenyl)-1,1,1-trichloroethane (DDT) as influenced by chemical charges in the molecule. J Pharmacol Exp Ther 87: 400–413Google Scholar
- 13.Reif VD, Sinsheimer JE, Ward JC, Schteingart DE (1974) Aromatic hydroxylation and alkyl oxidation in metabolism of mitotane (o,p′-DDD) in humans. J Pharm Sci 63: 1730–1736Google Scholar
- 14.Temple TW, Jones DJ, Liddel GW, Dexter RW (1969) Treatment of Cushing's disease. N Engl J Med 281: 801–805Google Scholar